|
|
Emerging targets in HDL modification: Relevant data from development programs
|
|
|
|
Novel Approaches to Modify Lipids and Lipoproteins
|
|
|
|
New Approaches for Raising HDL
|
|
|
|
The Verdict is Still Out on CETP Inhibition as a Mechanism
|
|
|
|
New Approaches for Raising HDL
|
|
|
|
Nicotinic AcidTreatment of Dyslipidemia and Atherosclerosis
|
|
|
|
ER Niacin Therapy
|
|
|
|
Effectiveness of 2 g vs 1 g of ER Niacin
|
|
|
|
Niacin Flushing Pathway: Two Separate Steps and Sites of Action
|
|
|
|
An Overview of the Niacin-Induced Flushing Pathway
|
|
|
|
Lipid/Flushing Study: Lower Incidence of Moderate or Greater Flushing vs ER Niacin
|
|
|
|
ER Niacin/Laropiprant Lipid Efficacy (Weeks 12-24)
|
|
|
|
Factorial Study: Lipid Efficacy
|
|
|
|
HPS2-THRIVE
|
|
|
|
New Approaches for Raising HDL
|
|
|
|
Where to Intervene in HDL-C Metabolism?
|
|
|
|
ApoA1 Based Therapies
|
|
|
|
ApoA-I is made in the Liver and Small Intestines.
|
|
|
|
RVX-208
|
|
|
|
RVX-208
|
|
|
|
Schematic of Phase 1a Protocol
|
|
|
|
Efficacy of RVX-208 in Humans
|
|
|
|
RVX208 α1-HDL Comparison vs. High Dose Statins α1-HDL
|
|
|
|
Cerenis HDL (CER-001) Homogeneous Drug Product
|
|
|
|
CER-001-CLIN-001 : 15 mg/kg LCAT Activation
|
|
|
|
CER-001 Mobilizes Cholesterol in Rabbits: Comparison with ETC-216
|
|
|
|
CHI SQUARE Study Design
|
|
|
|
CHI-SQUARE Study Design
|
|
|
|
CER-001-CLIN-001 Overall Conclusions
|
|
|
|
IVUS clinical trial using selective delipidated HDL
|
|
|
|
IVUS Clinical Trial Using Selective Delipidated HDL
|
|
|
|
Results of the IVUS Clinical Trial Using Selective Delipidated HDL
|
|
|
|
Conclusion
|
|
|
|
New Approaches for Raising HDL
|
|
|
|
LCAT Product Gradient Drives Reverse Cholesterol Transport
|
|
|
|
LCAT Deficiency in Humans
|
|
|
|
Impaired RCT in Familial LCAT Deficiency
|
|
|
|
Conclusion
|
|
Prof. John Kastelein
Kastelein (PPTX 3MB)
Share this page with your colleagues and friends: